아토피 피부염 시장 : 제품별, 투여 방법별, 중증도별, 환자 속성별, 유통 채널별 - 세계 예측(2025-2030년)

The Atopic Dermatitis Market was valued at USD 19.73 billion in 2023 and is projected to grow to USD 20.83 billion in 2024, with a CAGR of 5.88%, reaching USD 29.45 billion by 2030.

Atopic dermatitis has evolved from being a largely misunderstood skin condition to a focal point in dermatological research and market analytics. In recent years, increasing clinical awareness, combined with a deeper understanding of the underlying genetic and environmental factors, has reshaped the narrative around this chronic inflammatory disorder. Modern treatment paradigms now address not only physical symptoms such as itch and discomfort, but also the emotional and social burdens that patients endure. The rising global prevalence of the condition has led to an influx of innovative treatment modalities, investment in research and development, and an increasing number of clinical trials aimed at enhancing quality of life for those affected. The importance of patient-centric approaches has been recognized across key regions and various patient demographics, resulting in more targeted therapies and customized treatment protocols. This evolution is underscored by comprehensive market analysis where robust datasets and clinical insights have provided clearer guidance for healthcare providers and decision makers. The current landscape invites stakeholders to explore the interplay between emerging therapeutics, patient needs, and market dynamics, forging a path that promises improved outcomes and renewed hope for millions of individuals worldwide.

Transformative Shifts in the Atopic Dermatitis Landscape

The landscape of atopic dermatitis management has undergone transformative shifts, driven by technological advancements, evolving regulatory frameworks, and a surge in innovative therapeutic approaches. Breakthroughs in diagnostics and the advent of precision medicine have altered how clinicians diagnose and treat the condition, emphasizing early intervention and personalized treatment regimens. Regulatory bodies are increasingly supportive of adaptive clinical trials and accelerated pathways for novel therapies, providing the impetus for both established pharmaceutical companies and new entrants to invest in research. Innovative devices and non-traditional treatment options are gaining traction, reshaping treatment modalities that extend from conventional pharmacotherapy to advanced light-based interventions. Additionally, growing digitalization in healthcare-including telemedicine and mobile health applications-has enhanced patient monitoring and therapy adherence, making it easier to track the progression of the disease and adjust treatments in real time. As emerging scientific evidence continues to refine our understanding of atopic dermatitis, market participants are now rethinking their strategies, prioritizing flexible models that can rapidly adapt to new information and technological disruptions. This dynamic landscape signals not only exciting times for clinical advancements but also presents significant opportunities for market growth and improved patient outcomes.

Key Segmentation Insights

A deep dive into segmentation reveals crucial insights that are shaping the future of atopic dermatitis treatment and market strategies. Analysis by product shows that the market is primarily differentiated into light therapy and medication applications. Light therapy has seen rigorous studies encompassing Excimer Laser Therapy, PUVA Therapy, and UVB Therapy, each presenting distinct efficacy and safety profiles. Similarly, medications have been dissected into categories such as antibiotics, antivirals or antifungals, antihistamines, corticosteroids, Janus Kinase (JAK) inhibitors, monoclonal antibodies, and immunomodulators like pimecrolimus or tacrolimus, offering a wide spectrum of therapeutic options to suit diverse patient needs. Beyond product segmentation, an evaluation by mode of administration adds another layer of insight. Oral administration, carefully considered in terms of capsules and tablets, is complemented by parenteral routes, including both intramuscular and intravenous procedures, as well as topical applications in the form of creams, lotions, and ointments. Consideration of severity levels-ranging from mild, moderate, to severe atopic dermatitis-provides a nuanced approach in aligning treatments with clinical presentations. Patient demographics, split between adult and pediatric populations, illustrate the need for tailored interventions that address age-specific challenges and expectations. Lastly, understanding the role of distribution channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, helps in optimizing market access and patient reach. These interconnected layers of segmentation allow for a comprehensive understanding of current market dynamics, enabling precise targeting of therapies and more effective resource allocation.

Based on Product, market is studied across Light Therapy and Medication. The Light Therapy is further studied across Excimer Laser Therapy, PUVA Therapy, and UVB Therapy. The Medication is further studied across Antibiotics, Antivirals or Antifungals, Antihistamines, Corticosteroid, Janus Kinase (JAK) Inhibitors, Monoclonal Antibodies, and Pimecrolimus or Tacrolimus.

Based on Mode Of Administration, market is studied across Oral Administration, Parenteral Administration, and Topical Administration. The Oral Administration is further studied across Capsules and Tablets. The Parenteral Administration is further studied across Intramuscular and Intravenous. The Topical Administration is further studied across Cream, Lotion, and Ointment.

Based on Severity Level, market is studied across Mild Atopic Dermatitis, Moderate Atopic Dermatitis, and Severe Atopic Dermatitis.

Based on Patient Demographics, market is studied across Adult Patients and Pediatric Patients.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Market Dynamics

A thorough regional analysis indicates that market trends are distinctly influenced by geographic distinctions. In the Americas, strong infrastructure and high healthcare spending support advanced therapeutic implementation and robust clinical research environments. Within Europe, the Middle East, and Africa, evolving economic landscapes and shifting regulatory environments have spurred innovation, while enhanced access to modern therapeutics in these regions is gradually aligning with global standards. The Asia-Pacific region stands out due to its rapidly growing economies, expanding patient populations, and increasing awareness of chronic conditions. Advancements in healthcare infrastructure and ongoing investments in research and development are positioning this region as a key player in driving technological innovations and improved patient outcomes in the field of atopic dermatitis.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

In the corporate arena, several leading players are proactively shaping the future of atopic dermatitis treatment through strategic research and robust product pipelines. Innovators such as AbbVie Inc. and Amgen Inc. consistently drive breakthroughs, while companies like AstraZeneca PLC and Bausch Health Companies Inc. have harnessed the power of cross-disciplinary collaborations to push the boundaries of conventional therapies. Biofrontera AG and Bristol-Myers Squibb Company have demonstrated significant commitment by investing in advanced clinical trials, and firms such as Chugai Pharmaceutical Co., Ltd. and Daavlin Company have strategically positioned themselves within niche therapeutic segments. Esteemed industry giants including Eli Lilly and Company, F. Hoffmann-La Roche Ltd., and Galderma Holding SA continue to set high benchmarks for clinical efficacy, while GlaxoSmithKline PLC and Incyte Corporation further diversify the market with emerging therapeutic modalities. Johnson & Johnson Services Inc., LEO Pharma A/S, and Maruho Co., Ltd are leveraging their longstanding expertise to refine treatment protocols. Novartis AG, Perrigo Company PLC, Pfizer, Inc., and Regeneron Pharmaceuticals, Inc have adeptly responded to shifting market demands, while industry leaders from Sanofi SA, Solarc Systems Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., and Viatris Inc. complete a competitive landscape that is characterized by continual innovation and steadfast commitment to patient care.

The report delves into recent significant developments in the Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bausch Health Companies Inc., Biofrontera AG, Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Daavlin Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma Holding SA, GlaxoSmithKline PLC, Incyte Corporation, Johnson & Johnson Services Inc., LEO Pharma A/S, Maruho Co., Ltd, Novartis AG, Perrigo Company PLC, Pfizer, Inc., Regeneron Pharmaceuticals, Inc, Sanofi SA, Solarc Systems Inc., Teva Pharmaceutical Industries Ltd., UCB S.A., and Viatris Inc.. Actionable Recommendations for Industry Leaders

For industry leaders seeking to navigate and excel within the rapidly evolving atopic dermatitis market, several actionable recommendations emerge from the current data and market trends. First, it is imperative to invest in robust, data-driven research that not only examines traditional therapeutic options but also explores novel treatment modalities. Marketers should consider bolstering their capabilities in digital health technology, integrating telehealth platforms with advanced analytics to understand patient behavior in real time and facilitate personalized care plans. Embracing collaborations with academic institutions and clinical research organizations can further streamline the development of innovative clinical trials and fast-track the introduction of new therapies to the market. Additionally, aligning product development with precise segmentation-considering factors like mode of administration, product type, patient severity levels, and distinct demographic needs-can significantly enhance market penetration and optimize therapeutic outcomes. Leaders are also advised to fortify their distribution channels by leveraging partnerships with hospital, online, and retail pharmacies, ensuring maximum accessibility and timely delivery of treatments. Lastly, a proactive engagement with regulatory bodies through transparent communication and active participation in shaping health policies will not only facilitate quicker market approvals but also build strong credibility among stakeholders. These strategic recommendations are designed to help industry leaders create more tailored and impactful solutions that meet evolving patient demands and drive market growth.

Conclusion: Summing Up Key Findings

In conclusion, the atopic dermatitis market is experiencing a period of unprecedented transformation. Recent advances in treatment modalities, combined with evolving patient demographics and the integration of cutting-edge technology, have fundamentally shifted market dynamics. The nuanced analysis of product segmentation, including comprehensive studies across light therapy and medication strategies, highlights an industry that is poised for continued innovation. Regional trends further underscore the importance of localized strategies as emerging economies and developed markets alike adapt to new clinical realities. Key corporate players are not only investing heavily in research and clinical development but are also redefining their portfolios to meet complex patient needs. As the collective insights from cutting-edge research, advanced product segmentation, and dynamic regional analysis converge, stakeholders can confidently anticipate a future marked by enhanced patient outcomes and robust market growth. The ongoing evolution in treatment interventions and strategic market maneuvers presents a timely opportunity for industry authorities to secure a competitive advantage by aligning their strategies with emerging global trends.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of skin conditions and allergies globally boosts the demand for atopic dermatitis solutions
    • 5.1.1.2. Rising patient awareness and need for personalized therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with product recall in atopic dermatitis treatment products
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel non-steroidal therapeutic solutions
    • 5.1.3.2. Rising innovations in portable phototherapy devices for home-based atopic dermatitis treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Rising side effects concerns associated with atopic dermatitis treatment
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Significant benefits of corticosteroid to reduce swelling, redness, and itching
  • 5.2.2. Mode Of Administration: Proliferating adoption of oral administration mode due to ease of use and patient compliance
  • 5.2.3. Severity Level: Increasing usage of medication for the treatment of moderate atopic dermatitis
  • 5.2.4. Patient Demographics: Rising demand of atopic dermatitis treatment in adults for rapid symptom relief & to manage long-term symptoms effectively
  • 5.2.5. Distribution Channel: Growing preference for online pharmacies for acquiring medications from the comfort of their homes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Atopic Dermatitis Market, by Product

• 6.1. Introduction
• 6.2. Light Therapy
  • 6.2.1. Excimer Laser Therapy
  • 6.2.2. PUVA Therapy
  • 6.2.3. UVB Therapy
• 6.3. Medication
  • 6.3.1. Antibiotics, Antivirals or Antifungals
  • 6.3.2. Antihistamines
  • 6.3.3. Corticosteroid
  • 6.3.4. Janus Kinase (JAK) Inhibitors
  • 6.3.5. Monoclonal Antibodies
  • 6.3.6. Pimecrolimus or Tacrolimus

7. Atopic Dermatitis Market, by Mode Of Administration

• 7.1. Introduction
• 7.2. Oral Administration
  • 7.2.1. Capsules
  • 7.2.2. Tablets
• 7.3. Parenteral Administration
  • 7.3.1. Intramuscular
  • 7.3.2. Intravenous
• 7.4. Topical Administration
  • 7.4.1. Cream
  • 7.4.2. Lotion
  • 7.4.3. Ointment

8. Atopic Dermatitis Market, by Severity Level

• 8.1. Introduction
• 8.2. Mild Atopic Dermatitis
• 8.3. Moderate Atopic Dermatitis
• 8.4. Severe Atopic Dermatitis

9. Atopic Dermatitis Market, by Patient Demographics

• 9.1. Introduction
• 9.2. Adult Patients
• 9.3. Pediatric Patients

10. Atopic Dermatitis Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Americas Atopic Dermatitis Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Atopic Dermatitis Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Atopic Dermatitis Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Evommune secures USD 115 million Series C for advancement in chronic inflammatory disease therapies
  • 14.3.2. Organon enhances dermatology portfolio with strategic acquisition of dermavant and VTAMA Cream
  • 14.3.3. FDA approves Eli Lilly EBGLYSS for moderate to severe atopic dermatitis treatment
  • 14.3.4. Biofrontera and LEO Pharma entered an agreement to enhance dermatological treatments in Germany
  • 14.3.5. Arcutis Biotherapeutics launches ZORYVE cream for atopic dermatitis treatment
  • 14.3.6. Dermavant secures Japanese approval for tapinarof in psoriasis and atopic dermatitis
  • 14.3.7. Johnson & Johnson acquires Proteologix to enhance atopic dermatitis treatment portfolio
  • 14.3.8. Almirall partners with CRG to advance atopic dermatitis treatment research
  • 14.3.9. Glenmark and Pfizer collaborate to launch abrocitinib for atopic dermatitis in India
  • 14.3.10. Teva and Biolojic Design entered an agreement to develop innovative antibody therapy for atopic dermatitis and asthma
  • 14.3.11. IMIDomics and Bristol Myers Squibb expand partnership to advance atopic dermatitis research
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Eli Lilly and Company
  • 14.4.2. Pfizer Inc.
  • 14.4.3. Johnson & Johnson Services Inc.
  • 14.4.4. AbbVie Inc.

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Bausch Health Companies Inc.
• 5. Biofrontera AG
• 6. Bristol-Myers Squibb Company
• 7. Chugai Pharmaceutical Co., Ltd.
• 8. Daavlin Company
• 9. Eli Lilly and Company
• 10. F. Hoffmann-La Roche Ltd.
• 11. Galderma Holding SA
• 12. GlaxoSmithKline PLC
• 13. Incyte Corporation
• 14. Johnson & Johnson Services Inc.
• 15. LEO Pharma A/S
• 16. Maruho Co., Ltd
• 17. Novartis AG
• 18. Perrigo Company PLC
• 19. Pfizer, Inc.
• 20. Regeneron Pharmaceuticals, Inc
• 21. Sanofi SA
• 22. Solarc Systems Inc.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. UCB S.A.
• 25. Viatris Inc.